DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8.445,002 B2 Mansouri (45) Date of Patent: May 21, 2013

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 8.445,002 B2 Mansouri (45) Date of Patent: May 21, 2013 USOO8445002B2 (12) United States Patent (10) Patent No.: US 8.445,002 B2 Mansouri (45) Date of Patent: May 21, 2013 (54) DERMAL DELIVERY COMPOSITIONS (56) References Cited COMPRISING ACTIVE AGENT-CALCUM PHOSPHATE PARTICLE COMPLEXES AND U.S. PATENT DOCUMENTS METHODS OF USING THE SAME 4,948,575 A * 8/1990 Cole et al. ....................... 424/44 5,158,756 A * 10/1992 Ogawa et al. ...... ... 423.309 (75) Inventor: Zahra Mansouri, Tahoe City, CA (US) 5,604.200 A * 2/1997 Taylor-McCord ............. 514/9.3 6,096,324 A 8, 2000 Mansouri 6,120,782 A 9, 2000 Mansouri (73) Assignee: Laboratory Skin Care, Inc., Tahoe 6,262,020 B1* T/2001 Lezdey et al. .................. 514/5.9 City, CA (US) 6,395,311 B2* 5/2002 Jia .................. ... 424/744 6,573.249 B2 * 6/2003 Lezdey et al. ................... 514/54 (*) Notice: Subject to any disclaimer, the term of this 2002fOO18797 A1 2/2002 Cui et al. patent is extended or adjusted under 35 2005/00 13874 A1 1/2005 Ito et al. ........................ 424,602 2005/02341 14 A1 10, 2005 Lee U.S.C. 154(b) by 0 days. 2006/0257658 A1* 11/2006 Tanaka et al. ................. 428/402 2007, OOO3487 A1* 1/2007 Ek ............... ... 424/46 (21) Appl. No.: 12/742,235 2008/005.1335 A1 2/2008 Kleiner et al. .................. 514/12 2008, 0220233 A1 9/2008 Kjellin et al. (22) PCT Filed: May 6, 2010 2010/0086606 A1* 4/2010 Ogawa .......................... 424/489 2012/0130435 A1* 5, 2012 Hart et al. ...... ... 606,301 (86). PCT No.: PCT/US2O10/033942 2012/0134919 A1* 5/2012 Engqvist et al. ... 424,129 2012/0207803 A1* 8, 2012 Bell .............................. 424/401 S371 (c)(1), (2), (4) Date: Apr. 12, 2011 OTHER PUBLICATIONS Meisel M., "About Face, Anti-aging, natural products lead the thriv (87) PCT Pub. No.: WO2010/1298.19 ing skin care category Happi Household and Personal Products Industry. (May 7, 2008) web article: http://www.happi.com/articles/ PCT Pub. Date: Nov. 11, 2010 2008/05/about-face; 15 pp. (65) Prior Publication Data * cited by examiner US 2011 FO189239 A1 Aug. 4, 2011 Primary Examiner — Robert A Wax Assistant Examiner — Olga V Tcherkasskaya Related U.S. Application Data (74) Attorney, Agent, or Firm — Bozicevic, Field & Francis LLP: Bret E. Field (60) Provisional application No. 61/176,057, filed on May 6, 2009. (57) ABSTRACT Dermal delivery compositions are provided. Aspects of the (51) Int. Cl. dermal delivery compositions include the presence of active A6 IK9/00 (2006.01) agent-calcium phosphate particle complexes, where these A6 IK 9/14 (2006.01) complexes include uniform, rigid, spherical nanoporous cal (52) U.S. Cl. cium phosphate particles associated with one or more active USPC ........................................... 424/400; 424/489 agents. Also provided are methods of using the compositions (58) Field of Classification Search in active agent delivery applications. None See application file for complete search history. 18 Claims, 11 Drawing Sheets U.S. Patent May 21, 2013 Sheet 1 of 11 US 8.445,002 B2 FG 1A FG B U.S. Patent May 21, 2013 Sheet 2 of 11 US 8.445,002 B2 FIG. 2A FIG. 2B U.S. Patent May 21, 2013 Sheet 3 of 11 US 8.445,002 B2 FIG 3 :::::::::: U.S. Patent May 21, 2013 Sheet 4 of 11 US 8.445,002 B2 FG, 4A FIG 4B U.S. Patent May 21, 2013 Sheet 5 of 11 US 8.445,002 B2 FG 5A FG U.S. Patent May 21, 2013 Sheet 6 of 11 US 8.445,002 B2 FG 6 S. U.S. Patent May 21, 2013 Sheet 7 of 11 US 8.445,002 B2 FIG 7B FIG. 7A U.S. Patent May 21, 2013 Sheet 8 of 11 US 8.445,002 B2 F.G. 8 U.S. Patent May 21, 2013 Sheet 9 of 11 US 8.445,002 B2 FG. 9 6. ..). O . 5 U.S. Patent May 21, 2013 Sheet 10 of 11 US 8.445,002 B2 F.G. 10 Skin Delivered Lysozyme (ug) Skin Delivered Lysozyme (%) Tape With Without With Without layer Hydroxysomes" | Hydroxysomes" | Hydroxysomes' | Hydroxysomes' 1. 7.210 Lig 48.35 ug O60.0/ 4. O39/o 2 0.979 ug 0.56 ug O.O896 O.O470/6. 3 0.284 ig 0.03 ug O.O2/o O. O.02% 4 0.100 Ig 0.00 ug O. O.19 OOO 5 0.029 ug 0.00 ug OOO29. O.OO 6 0.024 ug 0.00 ug OOO29 O. OO U.S. Patent May 21, 2013 Sheet 11 of 11 US 8.445,002 B2 F.G. 1 US 8,445,002 B2 1. 2 DERMAL DELVERY COMPOSITIONS forearm. FIG. 5A shows calcium phosphate particle penetra COMPRISING ACTIVE AGENT-CALCUM tion to the first layer of the stratum corneum. FIG. 5B shows PHOSPHATE PARTICLE COMPLEXES AND calcium phosphate particle penetration to the third layer of METHODS OF USING THE SAME the stratum corneum. FIG. 6 is an image of mouse skin prior to application of CROSS-REFERENCE TO RELATED calcium phosphate particles. No Ca" is evident in the upper APPLICATIONS Statum COrneum. FIG. 7A shows calcium particles in the upper stratum cor Pursuant to 35 U.S.C. S 119 (e), this application claims neum as well as Smaller particles in the lower stratum cor priority to the filing date of U.S. Provisional Patent Applica 10 neum. FIG. 7B shows the loss of integrity of the spherical tion Ser. No. 61/176,057 filed May 6, 2009; the disclosure of calcium particles which application is herein incorporated by reference. FIG. 8 is a picture showing penetration of CTC fluorescent throughout the Stratum corneum following topical applica INTRODUCTION tion. 15 FIG. 9 shows the results of STAY-C50 with and without A variety of different active agents have been and continue calcium phosphate particle tape Stripping. to be developed for use in the treatment of a variety of differ FIG. 10 is a table showing amount and percentage of ent conditions, including both disease and non-disease con lysozyme with and without calcium phosphate particles as ditions. For Such applications, an effective amount of the measured by tape stripping. active agent must be delivered to the subject in need thereof. FIG. 11 shows Franz cell transdermal delivery of a ribo A variety of different delivery formulations and routes have flavin monophosphate active agent with and without calcium been developed, where such routes may vary depending on phosphate particles. the nature of the active agent. Typically, less invasive delivery routes are better tolerated and therefore are more desirable. DETAILED DESCRIPTION One type of delivery route that is of great interest because 25 of its minimally invasive nature is dermal delivery. In dermal Dermal delivery compositions are provided. Aspects of the delivery, an active agent composition is applied to a skin site dermal delivery compositions include the presence of active to deliver the active agent to the subject. Many dermal deliv agent-calcium phosphate particle complexes, where these ery technologies currently in use or under evaluation are not complexes include uniform, rigid, spherical nanoporous cal entirely satisfactory. For example, certain dermal delivery 30 cium phosphate particles associated with one or more active technologies may disrupt the integrity of the stratum corneum agents. Also provided are methods of using the compositions (Sc) and/or rely on the presence of permeation enhancers, in active agent delivery applications. which can cause unwanted damage and/or irritation. In addi Before the present invention is further described, it is to be tion, certain dermal delivery technologies may be polymer understood that this invention is not limited to particular and/or liposome based technologies, neither of which tech 35 embodiments described, as Such may vary. It is also to be nologies truly delivers through the Sc. Furthermore these understood that the terminology used herein is for the purpose technologies cannot be applied to large molecular weight of describing particular embodiments only, and is not bio-actives, etc. intended to be limiting, since the scope of the present inven As such, there continues to be a need for the development tion will be limited only by the appended claims. of new dermal delivery technologies which overcome one or 40 Where a range of values is provided, it is understood that more of the disadvantages experienced with current dermal each intervening value, to the tenth of the unit of the lower delivery approaches. limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or SUMMARY intervening value in that stated range, is encompassed within 45 the invention. The upper and lower limits of these smaller Dermal delivery compositions are provided. Aspects of the ranges may independently be included in the Smaller ranges dermal delivery compositions include the presence of active and are also encompassed within the invention, Subject to any agent-calcium phosphate particle complexes, where these specifically excluded limit in the stated range. Where the complexes include uniform, rigid, spherical nanoporous cal stated range includes one or both of the limits, ranges exclud cium phosphate particles associated with one or more active 50 ing either or both of those included limits are also included in agents. Also provided are methods of using the compositions the invention. in active agent delivery applications. Certain ranges are presented herein with numerical values being preceded by the term “about.” The term “about is used BRIEF DESCRIPTION OF THE FIGURES herein to provide literal support for the exact number that it 55 precedes, as well as a number that is near to or approximately FIGS.
Load more

Recommended publications
  • ECO-Ssls for Pahs
    Ecological Soil Screening Levels for Polycyclic Aromatic Hydrocarbons (PAHs) Interim Final OSWER Directive 9285.7-78 U.S. Environmental Protection Agency Office of Solid Waste and Emergency Response 1200 Pennsylvania Avenue, N.W. Washington, DC 20460 June 2007 This page intentionally left blank TABLE OF CONTENTS 1.0 INTRODUCTION .......................................................1 2.0 SUMMARY OF ECO-SSLs FOR PAHs......................................1 3.0 ECO-SSL FOR TERRESTRIAL PLANTS....................................4 5.0 ECO-SSL FOR AVIAN WILDLIFE.........................................8 6.0 ECO-SSL FOR MAMMALIAN WILDLIFE..................................8 6.1 Mammalian TRV ...................................................8 6.2 Estimation of Dose and Calculation of the Eco-SSL ........................9 7.0 REFERENCES .........................................................16 7.1 General PAH References ............................................16 7.2 References Used for Derivation of Plant and Soil Invertebrate Eco-SSLs ......17 7.3 References Rejected for Use in Derivation of Plant and Soil Invertebrate Eco-SSLs ...............................................................18 7.4 References Used in Derivation of Wildlife TRVs .........................25 7.5 References Rejected for Use in Derivation of Wildlife TRV ................28 i LIST OF TABLES Table 2.1 PAH Eco-SSLs (mg/kg dry weight in soil) ..............................4 Table 3.1 Plant Toxicity Data - PAHs ..........................................5 Table 4.1
    [Show full text]
  • OECD Environment Health and Safety Publications Series on Testing and Assessment No
    OECD Environment Health and Safety Publications Series on Testing and Assessment No. 21 Detailed Review Paper Appraisal of Test Methods for Sex Hormone Disrupting Chemicals Environment Directorate ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT Paris May 2001 1 Also Published in the Series Testing and Assessment: No. 1, Guidance Document for the Development of OECD Guidelines for Testing of Chemicals (1993; reformatted 1995) No. 2, Detailed Review Paper on Biodegradability Testing (1995) No. 3, Guidance Document for Aquatic Effects Assessment (1995) No. 4, Report of the OECD Workshop on Environmental Hazard/Risk Assessment (1995) No. 5, Report of the SETAC/OECD Workshop on Avian Toxicity Testing (1996) No. 6, Report of the Final Ring-test of the Daphnia magna Reproduction Test (1997) No. 7, Guidance Document on Direct Phototransformation of Chemicals in Water (1997) No. 8, Report of the OECD Workshop on Sharing Information about New Industrial Chemicals Assessment (1997) No. 9 Guidance Document for the Conduct of Studies of Occupational Exposure to Pesticides During Agricultural Application (1997) No. 10, Report of the OECD Workshop on Statistical Analysis of Aquatic Toxicity Data (1998) No. 11, Detailed Review Paper on Aquatic Testing Methods for Pesticides and industrial Chemicals (1998) No. 12, Detailed Review Document on Classification Systems for Germ Cell Mutagenicity in OECD Member Countries (1998) No. 13, Detailed Review Document on Classification Systems for Sensitising Substances in OECD Member Countries 1998) No. 14, Detailed Review Document on Classification Systems for Eye Irritation/Corrosion in OECD Member Countries (1998) No. 15, Detailed Review Document on Classification Systems for Reproductive Toxicity in OECD Member Countries (1998) No.
    [Show full text]
  • Lonsurf (Trifluridine/Tipiracil) Were Bone Marrow Suppression and Gastrointestinal Toxicity
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrLONSURF® trifluridine and tipiracil tablet 15 mg trifluridine/ 6.14 mg tipiracil (as tipiracil hydrochloride) 20 mg trifluridine / 8.19 mg tipiracil (as tipiracil hydrochloride) Antineoplastic Agent Thymidine phosphorylase inhibitor/nucleoside metabolic inhibitor Taiho Pharma Canada, Inc. Date of Initial Approval: 2010 Winston Park Drive, Suite 503 January 23, 2018 Oakville, Ontario L6H 5R7 Canada Submission Control No: 205852 Page 1 of 35 RECENT MAJOR LABEL CHANGES Not Applicable TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES ......................................................................................2 TABLE OF CONTENTS ..............................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION ............................................................4 1 INDICATIONS....................................................................................................................4 1.1 Pediatrics ....................................................................................................................4 1.2 Geriatrics ....................................................................................................................4 2 CONTRAINDICATIONS ..................................................................................................4 3 DOSAGE AND ADMINISTRATION ...............................................................................4 3.1 Dosing Considerations
    [Show full text]
  • Effect of Surfactant–Bile Interactions on the Solubility of Hydrophobic
    Article Cite This: Mol. Pharmaceutics 2018, 15, 5741−5753 pubs.acs.org/molecularpharmaceutics Effect of Surfactant−Bile Interactions on the Solubility of Hydrophobic Drugs in Biorelevant Dissolution Media Zahari Vinarov,*,† Vladimir Katev,† Nikola Burdzhiev,‡ Slavka Tcholakova,† and Nikolai Denkov† † Department of Chemical and Pharmaceutical Engineering, Faculty of Chemistry and Pharmacy, Sofia University, 1164 Sofia, Bulgaria ‡ Department of Organic Chemistry and Pharmacognosy, Faculty of Chemistry and Pharmacy, Sofia University, 1164 Sofia, Bulgaria *S Supporting Information ABSTRACT: Biorelevant dissolution media (BDM) methods are commonly employed to investigate the oral absorption of poorly water-soluble drugs. Despite the significant progress in this area, the effect of commonly employed pharmaceutical excipients, such as surfactants, on the solubility of drugs in BDM has not been characterized in detail. The aim of this study is to clarify the impact of surfactant−bile interactions on drug solubility by using a set of 12 surfactants, 3 model hydrophobic drugs (fenofibrate, danazol, and progesterone) and two types of BDM (porcine bile extract and sodium taurodeoxycholate). Drug precipitation and sharp nonlinear decrease in the solubility of all studied drugs is observed when drug-loaded ionic surfactant micelles are introduced in solutions of both BDM, whereas the drugs remain solubilized in the mixtures of nonionic polysorbate surfactants + BDM. One-dimensional and diffusion-ordered 1H NMR spectroscopy show that mixed bile salt + surfactant micelles with low drug solubilization capacity are formed for the ionic surfactants. On the other hand, separate surfactant-rich and bile salt-rich micelles coexist in the nonionic polysorbate surfactant + bile salt mixtures, explaining the better drug solubility in these systems.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0299054 A1 Chandar Et Al
    US 20080299054A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0299054 A1 Chandar et al. (43) Pub. Date: Dec. 4, 2008 (54) PERSONAL CARE COMPOSITIONS WITH Publication Classification ENHANCED FRAGRANCE DELVERY (51) Int. Cl. (75) Inventors: Prem Chandar, Closter, NJ (US); A6IR 8/34 (2006.01) Lin Yang, Woodbridge, CT (US) A6II 3/14 (2006.01) A6II 3/17 (2006.01) Correspondence Address: UNILEVER PATENT GROUP (52) U.S. Cl. .............. 424/54; 424/59: 424/65; 424/70.1; 800 SYLVANAVENUE, AG West S. Wing 514/588 ENGLEWOOD CLIFFS, NJ 07632-3100 (US) (57) ABSTRACT (73) Assignee: CONOPCO, INC., d/b/a UNILEVER, Englewood Cliffs, NJ A personal care product is provided which includes a fra (US) grance, a Substituted urea and a quaternary ammonium salt. The Substituted urea and quaternary ammonium salt operate (21) Appl. No.: 11/755,009 together as a scent boosting system to enhance Volatilization offragrance components upon the personal care composition (22) Filed: May 30, 2007 being first applied to human skin or hair. US 2008/0299054 A1 Dec. 4, 2008 PERSONAL CARE COMPOSITIONS WITH structure AB, wherein A is a cationic charged compo ENHANCED FRAGRANCE DELVERY nent of the salt AB, B is an anionic charged component of the salt AB, and BACKGROUND OF THE INVENTION 0013 A has a single quaternized nitrogen atom, at least two hydroxy groups and a molecular weight no 0001 1. Field of the Invention higher than about 250. 0002 The invention concerns personal care compositions which upon application to a human body Surface quickly release fragrance components thereby improving aesthetics DETAILED DESCRIPTION OF THE INVENTION of these compositions.
    [Show full text]
  • These Highlights Do Not Include All the Information Needed to Use LONSURF Safely and Effectively
    LONSURF- trifluridine and tipiracil tablet, film coated Taiho Pharmaceutical Co., Ltd. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LONSURF safely and effectively. See full prescribing information for LONSURF. LONSURF (trifluridine and tipiracil) tablets, for oral use Initial U.S. Approval: 2015 RECENT MAJOR CHANGES Indications and Usage (1.2) 2/2019 Recommended Dosage (2.1) 2/2019 Warnings and Precaution (5.1) 2/2019 INDICATIONS AND USAGE LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment of adult patients with: metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. (1.1) metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu- targeted therapy. (1.2) DOSAGE AND ADMINISTRATION Recommended Dosage: 35 mg/m2/dose orally twice daily with food on Days 1 through 5 and Days 8 through 12 of each 28-day cycle. (2.1) DOSAGE FORMS AND STRENGTHS Tablets: 15 mg trifluridine/6.14 mg tipiracil (3) 20 mg trifluridine/8.19 mg tipiracil (3) CONTRAINDICATIONS None. (4) WARNINGS AND PRECAUTIONS Severe Myelosuppression: Obtain complete blood counts prior to and on Day 15 of each cycle. Withhold and resume at next lower LONSURF dosage as recommended. (2.1, 5.1) Embryo-Fetal Toxicity: Can cause fetal harm.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Efficacy of Different Types of Therapy for COVID-19
    life Review Efficacy of Different Types of Therapy for COVID-19: A Comprehensive Review Anna Starshinova 1,*, Anna Malkova 2 , Ulia Zinchenko 3 , Dmitry Kudlay 4,5 , Anzhela Glushkova 6, Irina Dovgalyk 3, Piotr Yablonskiy 2,3 and Yehuda Shoenfeld 2,7,8 1 Almazov National Medical Research Centre, Head of the Research Department, 2 Akkuratov Str., 197341 Saint-Petersburg, Russia 2 Medical Department, Saint Petersburg State University, 199034 Saint-Petersburg, Russia; [email protected] (A.M.); [email protected] (P.Y.); [email protected] (Y.S.) 3 St. Petersburg Research Institute of Phthisiopulmonology, 199034 Saint-Petersburg, Russia; [email protected] (U.Z.); [email protected] (I.D.) 4 NRC Institute of Immunology FMBA of Russia, 115478 Moscow, Russia; [email protected] 5 Medical Department, I.M. Sechenov First Moscow State Medical University, 119435 Moscow, Russia 6 V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology, 192019 Saint Petersburg, Russia; [email protected] 7 Ariel University, Kiryat HaMada 3, Ariel 40700, Israel 8 Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer 5265601, Israel * Correspondence: [email protected]; Tel.: +7-9052043861 Citation: Starshinova, A.; Malkova, Abstract: A new coronavirus disease (COVID-19) has already affected millions of people in 213 coun- A.; Zinchenko, U.; Kudlay, D.; tries. The possibilities of treatment have been reviewed in recent publications but there are many Glushkova, A.; Dovgalyk, I.; controversial results and conclusions. An analysis of the studies did not reveal a difference in Yablonskiy, P.; Shoenfeld, Y. Efficacy mortality level between people treated with standard therapy, such as antiviral drugs and dexam- of Different Types of Therapy for ethasone, and new antiviral drugs/additional immune therapy.
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • Biodegradation of Linear Alkylbenzene Sulfonates
    BIODEGRADATION OF LINEAR ALKYLBENZENE SULFONATES Applicable to these current Stepan products: BIO-SOFT® D-40 BIO-SOFT® N-300 BIO-SOFT® N-411 BIO-SOFT® S-101 BIO-SOFT® S-101 LS BIO-SOFT® S-111 H BIO-SOFT® S-118 BIO-SOFT® S-120 NACCONOL® 40G NACCONOL® 90G POLYSTEP® A-15 POLYSTEP® A-15-30K STEPWET® DF-90 STEPANTAN® DT-60 BIO-SOFT® D-62 LT BIO-SOFT® L2P-123 POLYSTEP®A-15F Applicable to these inactive Stepan products: BIO-SOFT® D-53 BIO-SOFT® S-100 BIO-SOFT® S-130 POLYSTEP® A-13 POLYSTEP® A-4 POLYSTEP® A-7 STEPANTAN® DS-40 Biodegradation Information: Since their introduction in 1965, linear alkylbenzene sulfonates (LAS) have been used throughout the world as the main anionic surfactant in both household and industrial detergent products. As a result of their wide spread use, the biodegradation characteristics of LAS have been studied thoroughly under both laboratory and environmental conditions. Laboratory tests typically show that LAS will undergo rapid primary and ultimate biodegradation. Due to its favorable biodegradation characteristics, LAS is presently listed as a recommended control substance in the OECD "Readily Biodegradability: Closed Bottle Test". OECD Modified Sturm testing of a LAS product, BIO-SOFT® S-100, showed this product to be readily biodegradable. Primary biodegradation, which can reach 100% in 3 days, involves oxidation of the carbon atoms at the alkyl side chain to form transient, low toxicity sulfophenyl carboxylate intermediates. This is followed by complete breakdown characterized by cleavage of the aromatic ring and total mineralization to carbon dioxide, water and inorganic sulfonates.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8.470,756 B2 O’Brien (45) Date of Patent: Jun
    USOO8470756B2 (12) United States Patent (10) Patent No.: US 8.470,756 B2 O’Brien (45) Date of Patent: Jun. 25, 2013 (54) ECO-FRIENDLY LAUNDRY 6,995,127 B1 2/2006 Smith et al. PRETREATMENT COMPOSITIONS 7,077,870 B2 7/2006 Findlay et al. 7,250,174 B2 7/2007 Lee et al. 7,452,917 B2 11/2008 Baumoeller et al. (75) Inventor: Jeanne A. O’Brien, Racine, WI (US) 7,608,573 B1 10/2009 Scheuing et al. 7,618.931 B1 1 1/2009 Scheuing et al. (73) Assignee: S.C. Johnson & Son, Inc., Racine, WI 2002/0028755 A1* 3/2002 Van Dijk et al. .............. 510,392 2003, OO13629 A1 1/2003 Kischkelet al. (US) 2003/0027736 A1 2/2003 Raths et al. 2003/O122101 A1 7/2003 Prozzo et al. (*) Notice: Subject to any disclaimer, the term of this 2006.0053566 A1 3/2006 Prozzo et al. patent is extended or adjusted under 35 2006/010.5937 A1 5, 2006 Duran U.S.C. 154(b) by 312 days. 2007, OO 10416 A1 1, 2007 Wu et al. 2007/0179074 A1 8, 2007 Souter et al. 2007/O1968.98 A1 8, 2007 Nielsen et al. (21) Appl. No.: 12/405,862 2007/0275021 A1 11/2007 Lee et al. 2008/0000032 A1 1/2008 Wieprecht et al. (22) Filed: Mar 17, 2009 2008.0171683 A1 7/2008 Johnson et al. 2008/O187958 A1 8, 2008 Nielsen et al. (65) Prior Publication Data 2008. O194453 A1 8/2008 Lang 2009.0054294 A1 2/2009 Theiler US 2010/O144580 A1 Jun.
    [Show full text]
  • Personal Care Compositions with Silicones And
    (19) & (11) EP 1 804 922 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61Q 19/00 (2006.01) A61Q 1/02 (2006.01) 13.02.2008 Bulletin 2008/07 A61Q 19/10 (2006.01) A61Q 5/02 (2006.01) A61Q 5/12 (2006.01) A61Q 15/00 (2006.01) (2006.01) (2006.01) (21) Application number: 05797352.1 A61Q 11/00 A61K 8/896 A61K 8/891 (2006.01) A61K 8/58 (2006.01) A61K 8/898 (2006.01) A61K 8/41 (2006.01) (22) Date of filing: 24.10.2005 (86) International application number: PCT/EP2005/011416 (87) International publication number: WO 2006/045583 (04.05.2006 Gazette 2006/18) (54) PERSONAL CARE COMPOSITIONS WITH SILICONES AND DIHYDROXYPROPYL TRIALKYL AMMONIUM SALTS KÖRPERPFLEGEZUSAMMENSETZUNGEN MIT SILIKONEN UND DIHYDROXYPROPYL- TRIALKYL-AMMONIUMSALZEN COMPOSITIONS DE SOINS PERSONNELS COMPRENANT DES COMPOSES SILICONES ET DES SELS DE DIHYDROXYPROPYL TRIALKYL AMMONIUM (84) Designated Contracting States: • MINER, Philip E. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Unilever Home&Personal Care USA HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI Trumbull, CT 06611 (US) SK TR • BARROW, Stephen Unilever Home&Personal Care USA (30) Priority: 25.10.2004 US 972483 Trumbull, CT 06611 (US) 08.09.2005 US 222189 • CHANDAR, Prem Unilever Home&Personal Care USA (43) Date of publication of application: Trumbull, CT 06611 (US) 11.07.2007 Bulletin 2007/28 • MCMANUS, Richard Unilever Home&Personal Care USA (73) Proprietors: Trumbull, CT 06611 (US) • UNILEVER PLC • HARICHIAN, Bijan London, Greater London EC4P 4BQ (GB) Unilever T.
    [Show full text]